Abstract library

7 results for "polypectomy".
#2077 Linked Colour Imaging Increases the Diagnostic Yield of Type 1 Gastric Carcinoids
Introduction: Type 1 Gastric carcinoid tumours (GCTs) are the most common neuroendocrine tumours of the stomach. Endoscopic diagnosis of Type 1 GCTs remains a challenge. White light endoscopy (WLE) and Narrow Band Imaging (NBI) have failed to demonstrate reliable endoscopic signs of carcinoid.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Raj Srirajaskanthan
#927 Laparoscopic Antrectomy: A Safe and Definitive Treatment in Managing Type 1 Gastric Carcinoids
Introduction: Various type 1 gastric carcinoid (T1GC) treatments exist, including esophagastroduodenoscopy (EGD) observation, polypectomy, and antrectomy, but studies comparing treatment outcomes have been limited.
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: Hillary E. Jenny
#184 Somatostatin Analogues as a Therapeutic Option in a Series of 91 Patients with Gastric Carcinoids
Introduction: Gastric carcinoid tumors (GC) represent about 10-30% of carcinoid tumors and about 1% of all stomach neoplasms. They include three types : type 1 (70-85%), type 2 (5-10%) and type 3 (15-25%).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Christos St. Basagiannis
#406 YF476, a Gastrin Receptor Antagonist, Causes Regression of Tumors and Normalizes Serum Chromogranin A in Patients with Type 1 Gastric Carcinoids
Introduction: Chronic atrophic gastritis (CAG) results in achlorhydria, hypergastrinemia and, in some patients, gastric carcinoids (type 1 GCs). Type 1 GCs may become malignant and metastasize. Current treatments of type 1 GCs, such as polypectomy, somatostatin analogues and antrectomy, have their disadvantages. YF476 – a potent, selective, orally active and well-tolerated gastrin receptor antagonist in pre-clinical studies – prevented, as well as reduced, the number and size of gastric carcinoids and carcinomas in rodent models.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Reidar Fossmark
#533 Gastric Neuroendocrine Tumor Type 1 Associated with Autoimmune Polyglandular Syndrome Type 3B: A Case Report
Introduction: Gastric neuroendocrine tumors (GNET) are most commonly associated with pernicious anemia and hypergastrinemia. The coexistence with other endocrinological deficiencies is uncommon.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Ivan Kruljac
#1715 Recurrence of 6mm Rectal Neuroendocrine Tumor, 14 Years after Excision
Introduction: Rectal neuroendocrine tumours (NET) constitute 25% of all the digestive NET. Predictive factors of distant metastasis are: size greater than 1cm, high proliferative index and muscularis or lymphovascular invasion. In the absence of these criteria, some authors advocate there is no need for long-term follow-up.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Bernardo Marques
#1819 Initial Experience of a Novel Endoscopic Full Thickness Resection Device (FTRD) for the Treatment of Rectal Neuroendocrine Tumours
Introduction: Standard endoscopic resection of rectal NETs is often associated with histological incomplete excision due to submucosal position within the bowel. Endoscopic full thickness resection may allow early definitive management.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: John Knight
Authors: Fong M, Ramsey E, Boger P, Ellis R, ...